Solid Tumors and Oncology
ORIC Pharmaceuticals Inc. supports clinical research in advanced solid tumors with a focus on cancers driven by EGFR or HER2 alterations. The sponsor’s portfolio reflects interest in targeted cancer therapy across difficult-to-treat tumor types.
- Advanced solid tumor malignancies
- EGFR-altered cancers
- HER2-altered cancers
Research activity in this area is centered on molecularly defined oncology populations and treatment strategies for metastatic disease.
Prostate Cancer
The sponsor also funds clinical research in metastatic prostate cancer, with attention to disease settings where new therapeutic options are needed. This includes investigation of agents intended for men with advanced genitourinary cancer.
- Metastatic prostate cancer
- Genitourinary oncology
- Advanced hormone-sensitive and resistant disease
The sponsor’s clinical interests extend to treatment approaches for progressing disease in the prostate cancer setting.
EGFR and HER2-Directed Therapy
ORIC Clinical is engaged in research on cancers characterized by EGFR and HER2 pathway alterations, highlighting a therapeutic emphasis on oncogenic signaling targets relevant to tumor growth and survival.
- Receptor tyrosine kinase alterations
- Biomarker-defined cancer subsets
- Targeted antineoplastic therapy
This area of interest spans precision oncology approaches for patients with molecularly selected solid tumors.
Combination Cancer Treatment
Clinical research sponsored by ORIC Pharmaceuticals Inc. includes evaluation of combination regimens in solid tumors, with attention to pairing investigational oncology agents with established chemotherapy backbones.
- Combination antineoplastic therapy
- Chemotherapy-based treatment strategies
- Advanced cancer management
The sponsor’s therapeutic focus remains within oncology, especially settings where combination treatment is being explored for metastatic and genomically selected disease.
